SAN MATEO, Calif., July 15 /PRNewswire/ — Merz Aesthetics
today announced it is now shipping Asclera™ (polidocanol)
Injection sclerotherapy treatment to doctors’ offices throughout
the U.S. Previously only available in Europe, Asclera™ was recently
approved by the U.S. Food and Drug Administration (FDA).
In a study published in the June issue of Phlebology,
leading experts conclude that polidocanol is a highly effective
sclerotherapy treatment.
Asclera™ was approved by the FDA on March 30 to treat uncomplicated spider
veins (varicose veins less than or equal to 1 mm in diameter) and
uncomplicated reticular veins (varicose veins 1 to 3 mm in
diameter) in the lower extremities. It has not been studied in
larger varicose veins greater than 3 mm in diameter. Once injected,
it acts by damaging the cell lining of blood vessels, causing them
to close and eventually disappear.
Clinical support for Asclera™ continues to grow. In
the recent Phlebology study, the authors found that
polidocanol demonstrated significant efficacy over other treatment
options, like sodium tetradecyl sulfate (STS) 1%. In addition,
patients reported better satisfaction with polidocanol than with
other treatment options. Highlights from the study include:
- The treatment success rate for polidocanol was 95% at week 12
and 95% at week 26 vs. 92% and 91% for STS, respectively; both were
significantly higher than placebo (P< 0.0001). - The majority of patients treated with polidocanol were
satisfied with the treatment.- 87% at week 12 and 84% at week 26 for patient
‘/>”/>
- 87% at week 12 and 84% at week 26 for patient